Clinical trials: Adult Glioblastoma
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
This phase I/II trial is studying the side effects and the best dose of RO4929097 to see how well it works when given together with bevacizumab compared to bevacizumab alone in treating patients with progressive or recurrent…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01189240
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Glioma, Malignant
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
Pear Bio has developed a 3D microtumor assay and computer vision pipeline through which the response of an individual patient's tumor to different anti-cancer regimens can be tested simultaneously ex vivo.
- Conditions
- Brain Tumor, Glioma, Malignant, Ependymoma, Oligodendroglioma
- Trial name
- PEAR-GLIO (NCT06038760)
- Testing
- Resection
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Ourotech, Inc.
Brain and Central Nervous System Tumors
Suramin in Treating Patients With Recurrent Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with recurrent primary…
- Trial name
- NCT00002639
- Testing
- chemotherapy, suramin
- Where
- United States
- Sponsor
- Emory University
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
RATIONALE: Collecting fluid from a brain tumor using a small catheter may help doctors learn how much methotrexate gets into the tumor to kill the tumor cells.
- Trial name
- NCT00463008
- Testing
- methotrexate, pharmacological study
- Volunteers
- 12 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma, Glioblastoma Multiforme
Study of Pamiparib in Newly Diagnosed and rGBM
This is an open-label, single-center Phase 0/2 study that will enroll up to 30 participants with newly diagnosed (N=12) and recurrent glioblastoma (N=18).
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
- Trial name
- NCT04614909
- Testing
- Pamiparib, Olaparib, Radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nader Sanai
Adult Brain Glioblastoma, Recurrent Adult Brain Neoplasm
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
This phase II trial studies the safety of NovoTTF-100A in combination with bevacizumab and carmustine and to see how well they work in treating patients with glioblastoma multiforme that has returned for the first time.
- Trial name
- NCT02348255
- Testing
- Electric Field Therapy, Bevacizumab, Carmustine
- Where
- 2 sites in United States
- Sponsor
- University of California, Davis
Brain Neoplasms, Central Nervous System Neoplasms
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
The goal of Part I of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given with bevacizumab to patients with glioblastoma.
- Trial name
- NCT01582152
- Testing
- TPI287, Bevacizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking some of the blood flow to the tumor.
- Trial name
- NCT00553150
- Testing
- everolimus, temozolomide, radiation
- Where
- 178 sites in United States
- Volunteers
- 122 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Glioblastoma, Gliosarcoma
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
This trial studies the side effects of partial brain radiation therapy, temozolomide, chloroquine, and tumor treating fields therapy for the treatment of newly diagnosed glioblastoma.
- Trial name
- NCT04397679
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals
Brain and Central Nervous System Tumors
Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors
RATIONALE: New imaging procedures, such as functional magnetic resonance imaging and 1H-nuclear magnetic resonance spectroscopic imaging, may improve the ability to detect the extent of cancer in the brain.
- Trial name
- NCT00005083
- Testing
- conventional surgery, magnetic resonance imaging, magnetic resonance spectroscopic imaging
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Immunotoxin Therapy in Treating Patients With Malignant Glioma
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for malignant glioma.
- Trial name
- NCT00006268
- Testing
- cintredekin besudotox, isolated perfusion, conventional surgery
- Where
- 11 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Glioblastoma, Gliosarcoma
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354913
- Testing
- hydroxyurea, imatinib mesylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Neoplasms, Glioblastoma, Adult
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
This trial is a single-arm, open-label, first-in-human study of CS231295, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion.
- Conditions
- Neoplasms, Glioblastoma, Adult, Small Cell Lung Carcinoma (SCLC)
- Trial name
- NCT06902350
- Testing
- CS231295
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Advanced Malignancy, Advanced Solid Tumors
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
First in human, open-label, sequential dose escalation and expansion study of AMG 232 in subjects with advanced solid tumors or multiple myeloma
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT01723020
- Testing
- AMG 232
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 107 people
- Sponsor
- Kartos Therapeutics, Inc.
Glioblastoma Multiforme, Adult
UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3)
The goal of this study is to test whether an adaptive radiation therapy (RT), two-phase approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach.
- Trial name
- UNITED-3 (NCT05720078)
- Testing
- Adaptive, two-phase RT
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Sunnybrook Health Sciences Centre
Brain and Central Nervous System Tumors
Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma
Phase I/II trial to study the effectiveness of pyrazoloacridine plus carboplatin in treating patients who have recurrent glioma.
- Trial name
- NCT00005976
- Testing
- carboplatin, pyrazoloacridine
- Where
- 23 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following…
- Trial name
- NCT00004147
- Testing
- incyclinide
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium